Company news
Innovent Biologics, Inc. (HKEX:1801) news
Innovent Biologics, Inc. news releases on 6ix. Latest, Sep 29, 2026: 2026 INTERIM REPORT
Press releases & updates
2026 INTERIM REPORT
September 29, 2026
VOLUNTARY ANNOUNCEMENT - JAYPIRCA (PIRTOBRUTINIB) APPROVED IN CHINA FOR A NEW INDICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) ACROSS ALL LINES OF THERAPY
September 28, 2026
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squamous NSCLC
September 27, 2026
Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
September 22, 2026
Innovent Announces 2026 Interim Results and Business Updates
August 25, 2026
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
August 9, 2026
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
July 14, 2026
Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
June 30, 2026
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
June 21, 2026
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
June 4, 2026
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
May 31, 2026
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
May 31, 2026
Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
May 28, 2026
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
May 21, 2026
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
May 10, 2026
Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
April 21, 2026
Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
April 9, 2026
Altruist Biologics' Hangzhou Facility Secures First Commercial Manufacturing License
April 8, 2026
Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
March 30, 2026
Innovent Announces 2025 Annual Results and Business Updates
March 26, 2026
The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China
March 23, 2026
Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study
March 22, 2026
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
March 1, 2026
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
February 12, 2026
Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology
February 8, 2026
Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
January 26, 2026
Innovent's Partner Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
January 8, 2026
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
December 25, 2025
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
December 17, 2025
Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
December 11, 2025
Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody
December 9, 2025
Innovent Announces PECONDLE® (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis
December 8, 2025
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
December 7, 2025
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
December 6, 2025
Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies
December 4, 2025
China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
November 28, 2025
Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population
November 25, 2025
Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value
November 23, 2025
Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints
November 19, 2025
Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
November 9, 2025
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
November 4, 2025
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
October 26, 2025
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
October 21, 2025
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
September 19, 2025
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
September 17, 2025
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
September 15, 2025
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
September 10, 2025
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
September 7, 2025
Innovent Announces 2025 Interim Results and Business Updates
August 27, 2025
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
August 24, 2025